FDA Inspection 1296860 — Hubei Biocause Heilen Pharmaceutical Co., Ltd.
The FDA completed an inspection of Hubei Biocause Heilen Pharmaceutical Co., Ltd. on November 14, 2025 in Jingmen. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- November 14, 2025
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Jingmen (China)